Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 05-Sep-24 4:04 PM View:  | Burrows Scott L Chief Financial Officer | Spyre Therapeutics, Inc. (SYRE) | 03-Sep-24 | Private Sale | 18,531 | $28.17 | $522,074.00 | (14%) 134.95K to 116.42K | |
| 25-Apr-24 4:55 PM View: | Fairmount Funds Management ... Director | Spyre Therapeutics, Inc. (SYRE) | 25-Apr-24 | Option Exercise | 3,639,680 | -- | -- | 306% 1.19M to 4.83M | |
| 20-Feb-24 9:21 PM View: | Turtle Cameron Chief Executive Officer Director | Spyre Therapeutics, Inc. (SYRE) | 15-Feb-24 | Grant | 400 | $9.82 | $3,928.00 | < 1% 746.51K to 746.91K | |
| 29-Dec-23 5:00 PM View: | Fairmount Funds Management ... Director 10% Owner | Spyre Therapeutics, Inc. (SYRE) | 29-Dec-23 | Acquisition (other) | 812,076 | -- | -- | 21% 3.81M to 4.63M | |
| 29-Dec-23 5:00 PM View: | Fairmount Funds Management ... Director 10% Owner | Spyre Therapeutics, Inc. (SYRE) | 29-Dec-23 | Disposition (other) | 3,435,480 | -- | -- | (74%) 4.63M to 1.19M | |
| 22-Dec-23 6:00 PM View: | Burrows Scott L Chief Financial Officer | Spyre Therapeutics, Inc. (SYRE) | 22-Dec-23 | Grant | 134,953 | -- | -- | 100% 0 to 134.95K | |
| 28-Nov-23 4:05 PM View: | Fairmount Funds Management ... Director 10% Owner | Spyre Therapeutics, Inc. (SYRE) | 24-Nov-23 | Conversion | 3,435,480 | -- | -- | 908% 378.42K to 3.81M | |
| 27-Nov-23 4:25 PM View: | Turtle Cameron Chief Executive Officer Director | Spyre Therapeutics, Inc. (SYRE) | 24-Nov-23 | Conversion | 723,440 | -- | -- | 3136% 23.07K to 746.51K | |
| 25-Aug-22 7:37 PM View: | Souza Marcio Director | Spyre Therapeutics, Inc. (SYRE) | 25-Aug-22 | Private Purchase | 90,000 | $0.56 | $50,472.00 | 100% 0 to 90.0K | |
| 10-Jun-22 6:24 PM View: | Hanley Jr. Michael Conick Chief Commercial Officer | Spyre Therapeutics, Inc. (SYRE) | 08-Jun-22 | Private Purchase | 28,200 | $0.71 | $20,022.00 | 353% 8.0K to 36.2K | |
| 18-Mar-22 6:46 AM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 16-Mar-22 | Private Purchase | 80,079 | $2.34 | $187,705.00 | 11% 736.76K to 816.84K | |
| 15-Mar-22 6:32 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 15-Mar-22 | Purchase | 42,417 | $1.86 | $78,942.30 | 6% 697.34K to 739.76K | |
| 15-Mar-22 6:32 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 14-Mar-22 | Purchase | 67,472 | $1.93 | $130,221.00 | 11% 629.87K to 697.34K | |
| 15-Mar-22 6:30 PM View: | Alspaugh Jonathan Chief Financial Officer | Spyre Therapeutics, Inc. (SYRE) | 11-Mar-22 | Private Purchase | 75,000 | $2.08 | $156,000.00 | 83% 90.37K to 165.37K | |
| 15-Mar-22 6:32 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 11-Mar-22 | Private Purchase | 34,777 | $2.06 | $71,779.70 | 6% 595.09K to 629.87K | |
| 13-Dec-21 8:41 PM View: | Shanafelt Armen Director | Spyre Therapeutics, Inc. (SYRE) | 13-Dec-21 | Purchase | 14,685 | $3.65 | $53,600.20 | 11% 135.31K to 150.0K | |
| 13-Dec-21 8:39 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 10-Dec-21 | Purchase | 10,526 | $3.75 | $39,472.50 | 2% 584.56K to 595.09K | |
| 13-Dec-21 8:41 PM View: | Shanafelt Armen Director | Spyre Therapeutics, Inc. (SYRE) | 10-Dec-21 | Purchase | 13,516 | $3.65 | $49,333.40 | 11% 121.8K to 135.31K | |
| 13-Dec-21 8:37 PM View: | Alspaugh Jonathan Chief Financial Officer | Spyre Therapeutics, Inc. (SYRE) | 09-Dec-21 | Private Purchase | 50,000 | $3.72 | $186,000.00 | 124% 40.37K to 90.37K | |
| 13-Dec-21 8:39 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 09-Dec-21 | Private Purchase | 43,108 | $3.70 | $159,500.00 | 8% 541.46K to 584.56K | |
| 13-Dec-21 8:41 PM View: | Shanafelt Armen Director | Spyre Therapeutics, Inc. (SYRE) | 09-Dec-21 | Private Purchase | 121,799 | $3.67 | $446,759.00 | 100% 0 to 121.8K | |
| 14-Feb-22 10:00 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 20-Oct-21 | Gift | 10,000 | -- | -- | 2% 595.09K to 605.09K | |
| 14-Feb-22 10:00 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 20-Oct-21 | Gift | 10,000 | -- | -- | (2%) 605.09K to 595.09K | |
| 14-Feb-22 10:00 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 18-Oct-21 | Gift | 23,809 | -- | -- | (4%) 618.9K to 595.09K | |
| 14-Feb-22 10:00 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 18-Oct-21 | Gift | 23,809 | -- | -- | 4% 595.09K to 618.9K | |
| 14-Feb-22 10:00 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 14-Oct-21 | Gift | 175,036 | -- | -- | 29% 595.09K to 770.13K | |
| 14-Feb-22 10:00 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 14-Oct-21 | Gift | 175,036 | -- | -- | (23%) 770.13K to 595.09K | |
| 18-Aug-21 5:21 PM View: | Alspaugh Jonathan Chief Financial Officer | Spyre Therapeutics, Inc. (SYRE) | 18-Aug-21 | Market Purchase | 7,200 | $6.72 | $48,399.80 | 22% 33.17K to 40.37K | (3%) |
| 18-Aug-21 5:21 PM View: | Alspaugh Jonathan Chief Financial Officer | Spyre Therapeutics, Inc. (SYRE) | 17-Aug-21 | Market Purchase | 23,392 | $6.50 | $151,985.00 | 239% 9.78K to 33.17K | < 1% |
| 18-Aug-21 5:21 PM View: | Alspaugh Jonathan Chief Financial Officer | Spyre Therapeutics, Inc. (SYRE) | 16-Aug-21 | Market Purchase | 9,780 | $6.37 | $62,275.10 | 100% 0 to 9.78K | 2% |
| 04-May-20 7:30 AM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 30-Apr-20 | Private Purchase | 165,000 | $4.75 | $783,750.00 | 44% 373.47K to 538.47K | |
| 07-Oct-19 4:09 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 04-Oct-19 | Option Exercise | 18,265 | $6.28 | $114,689.00 | 5% 353.64K to 371.91K | (2%) |
| 14-Jun-19 5:22 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 14-Jun-19 | Market Purchase | 5,282 | $6.23 | $32,912.70 | 2% 348.36K to 353.64K | (1%) |
| 14-Jun-19 5:22 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 13-Jun-19 | Market Purchase | 14,406 | $6.17 | $88,836.00 | 4% 333.95K to 348.36K | (< 1%) |
| 14-Jun-19 5:22 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 12-Jun-19 | Market Purchase | 12,217 | $6.11 | $74,704.50 | 4% 321.74K to 333.95K | < 1% |
| 22-May-19 4:55 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 22-May-19 | Market Purchase | 3,809 | $6.86 | $26,128.20 | 1% 317.93K to 321.74K | < 1% |
| 22-May-19 4:55 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 21-May-19 | Market Purchase | 13,794 | $6.89 | $94,981.40 | 5% 304.13K to 317.93K | < 1% |
| 22-May-19 4:55 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 20-May-19 | Market Purchase | 8,989 | $6.55 | $58,922.90 | 3% 295.15K to 304.13K | 6% |
| 17-May-19 5:04 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 17-May-19 | Market Purchase | 6,218 | $6.65 | $41,335.40 | 2% 288.93K to 295.15K | |
| 17-May-19 5:04 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 16-May-19 | Market Purchase | 5,520 | $6.83 | $37,690.60 | 2% 283.41K to 288.93K | |
| 17-May-19 5:04 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 15-May-19 | Market Purchase | 6,256 | $6.76 | $42,269.30 | 2% 277.15K to 283.41K | |
| 17-May-19 5:04 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 15-Feb-19 | Private Purchase | 719 | $7.10 | $5,103.46 | < 1% 276.43K to 277.15K | |
| 08-Feb-19 4:15 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 06-Feb-19 | Option Exercise | 8,756 | $6.18 | $54,125.80 | 3% 267.68K to 276.43K | |
| 14-Feb-22 10:00 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 28-Dec-18 | Gift | 57,450 | -- | -- | 14% 420.05K to 477.5K | |
| 14-Feb-22 10:00 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 28-Dec-18 | Gift | 57,450 | -- | -- | (12%) 477.5K to 420.05K | |
| 10-Dec-18 5:40 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 07-Dec-18 | Option Exercise | 171,890 | $4.37 | $751,816.00 | 179% 95.79K to 267.68K | |
| 28-Sep-18 5:11 PM View: | Schuchart Aaron Chief Business Officer | Spyre Therapeutics, Inc. (SYRE) | 27-Sep-18 | Market Sale | 6,000 | $9.50 | $57,005.00 | (71%) 8.5K to 2.5K | 12% |
| 21-Aug-18 4:24 PM View: | Schuchart Aaron Chief Business Officer | Spyre Therapeutics, Inc. (SYRE) | 17-Aug-18 | Option Exercise | 8,500 | $3.50 | $29,750.00 | 100% 0 to 8.5K | |
| 10-Dec-18 5:40 PM View: | Quinn Anthony President & CEO Director | Spyre Therapeutics, Inc. (SYRE) | 15-Aug-18 | Market Purchase | 994 | $9.13 | $9,075.22 | 1% 94.79K to 95.79K | (9%) |
| 15-Aug-18 4:40 PM View: | Georgiou George Director | Spyre Therapeutics, Inc. (SYRE) | 13-Aug-18 | Option Exercise | 37,333 | $5.91 | $220,784.00 | 27% 138.53K to 175.86K | 10% |
